Systemic Insecurity: FDA Turnover Exacerbates Rare Disease Drug Development Uncertainty
Original framing: “STAT+: Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development” — STAT News
Comparing the FDA's regulatory approach to that of other countries, such as Japan and the UK, highlights the importance of considering different cultural and societal contexts in shaping regulatory policies. These countries have developed unique approaches to regulating pharmaceuticals that prioritize public health and safety over industry interests.
The current regulatory environment for rare disease drug development is unsustainable and prioritizes industry interests over public health and safety.
To address this, we need to strengthen FDA regulatory policies, increase patient engagement, develop more robust regulatory frameworks, and invest in rare disease research. By taking a more patient-centered and public health-focused approach, we can ensure that rare disease drug development is driven by the needs of patients rather than profits.